Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma’s TO 6, Running Until March 31, 2025

Uppsala, Sweden, March 13, 2025. Major shareholders in Dicot Pharma and all members of the board and management holding warrants of series TO 6 have declared their intention to exercise them. This corresponds to a total investment of approximately SEK 11 million, or about 24 percent of the total outstanding warrants. The subscription period for TO 6 runs March 17 until March 31, 2025.

“It is very pleasing that we are once again seeing strong support from our major shareholders, board and management. This confidence means a lot and it feels extra valuable to be able to announce this even before the subscription period has begun”, says Elin Trampe, CEO.

One warrant of series TO 6 entitles to subscribe for two new shares at SEK 0.19 per share. To prevent the warrants from expiring worthless, the holder must actively subscribe for shares by March 31, 2025, or alternatively sell the warrants by March 27, 2025.

If all warrants are exercised for the subscription of new shares, Dicot Pharma will receive approximately SEK 45.7 million before issuance costs.

The terms and conditions regarding the warrants are available on Dicot Pharma’s website www.dicotpharma.com.